What Researchers Did
Two researchers reviewed updated approaches to classifying and treating perianal fistulizing Crohn's disease (PFCD), a severe complication where tunnels form between the anal canal and surrounding skin, with a focus on the new TOpClass classification system.
What They Found
The TOpClass system integrates patient anatomy and goals to guide individualized treatment. Emerging drugs like upadacitinib (a JAK inhibitor) show promise. Fistula conditioning with curettage and internal opening closure, an underused surgical technique, combined with adjunctive therapies including HBOT, has shown promise in promoting wound healing in selected patients.
What This Means for Canadian Patients
For Canadians with Crohn's disease complicated by perianal fistulas, a painful and treatment-resistant condition, HBOT is increasingly recognized as a useful add-on therapy alongside surgery and biologics. The TOpClass framework may help Canadian gastroenterologists and surgeons select the right patients for HBOT referral.
Canadian Relevance
No direct Canadian connection identified. Perianal fistulizing Crohn's disease is not a standard OHIP-covered indication for HBOT.
Study Limitations
This is a narrative review summarizing emerging data; the role of HBOT specifically is discussed briefly without dedicated systematic analysis.